Difficulty retrieving words (anomia) in people with relapsing-remitting multiple sclerosis (RR-MS)

Anomia in people with relapsing-remitting multiple sclerosis: investigating the nature and extent of the problem and taking steps toward better assessment and treatment.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN54123111

Enrollment

Registered

2018-03-15

Start date

2017-10-01

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anomia in patients with relapsing-remitting multiple sclerosis Mental and Behavioural Disorders Anomia

Interventions

PHASE I The first phase will involve an interview and a one-time communication screening. It will be a 1:1 session.. In the interview participants will be asked their n

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of RR-MS 2. English as a first language 3. Access to a laptop/tablet/PC to take part in treatment and homework exercises

Exclusion criteria

Exclusion criteria: 1. Severe dysarthria (sufficient to make words produced unintelligible) 2. Cardiac pacemaker or defibrillator implanted 3. Insulin or infusion pump implanted 4. Cochlear, otologic, or ear implant 5. Any implant held in place by a magnet 6. Tissue expanders (plastic surgery) 7. Implanted catheter, clamp, clips, valves, or other metal 8. Tattoos or permanent makeup above shoulders 9. Shrapnel or metal fragments in body 10. Ever had metal removed from eye 11. Ever worked as a metal worker 12. Pregnant

Design outcomes

Primary

Measure	Time frame
The primary outcome for the study is the determination of the extent and nature of the problem of anomia in RR-MS measured as percentage naming accuracy on a bespoke naming test, and also changes on this naming test as a result of anomia treatment. . The results for the extent of anomia in MS patients will be measured on participants global and individual performance on cognitive assessments and correlational and regression analyses with regard to linguistic or non-linguistic cognitive factors contributing to anomia severity. The nature of anomia will be measured by analysing MRI data using probabilistic tract mapping and anatomical connectivity mapping. Improvement of anomia symptoms will be measured using a case-series neuropsychological therapy study, allowing a single case comparison and cross-case comparison to therapy in relation to anomic severity.	—

Measure

Time frame

The primary outcome for the study is the determination of the extent and nature of the problem of anomia in RR-MS measured as percentage naming accuracy on a bespoke naming test, and also changes on this naming test as a result of anomia treatment. . The results for the extent of anomia in MS patients will be measured on participants global and individual performance on cognitive assessments and correlational and regression analyses with regard to linguistic or non-linguistic cognitive factors contributing to anomia severity. The nature of anomia will be measured by analysing MRI data using probabilistic tract mapping and anatomical connectivity mapping. Improvement of anomia symptoms will be measured using a case-series neuropsychological therapy study, allowing a single case comparison and cross-case comparison to therapy in relation to anomic severity.

—

Secondary

Measure	Time frame
The primary outcome measure will be interpreted in the context of participants' global and individual performance on cognitive screening using the Addenbroke’s Cognitive Examination (ACE-R), the Picture Naming Task (IPNP), the National Adult Reading Test (IPNP) and Pyramids and Palm Trees (PPT) Test at baseline. Also correlational and regression analyses will be used to explore if other factors such as, time of diagnosis or number of relapses collected by reviewing the participant’s medical records contribute to anomia. The nature of anomia will be interpreted through in-depth neuropsychological assessment, along with the knowledge of the areas of the brain that have been affected by MS. A one-time MRI scan of each participant 3 months after the cognitive screening and an in-depth neuropsychological assessment including the Western Aphasia Battery (WAB), the Boston Naming Test (BNT), the Wisconsin Card Sort Test (WST), Test of Everyday Attention (TEA) and the Symbol Digits Modality Test (SDMT) within a week of the scan will be used. A probabilistic tract mapping and anatomical connectivity mapping will be conducted on the diffusion data to examine white matter tissue integrity. Both the lesion and white matter integrity measures will be related to performance using voxel based correlational methodology. The resting-state functional connectivity data will be processed via DPARSF (http://rfmri.org/DPARSF), and the resulting functional networks will be identified and examined in relation to both the behavioural and structural connectivity data. MS lesions will be identified manually from the T1 and T2 scans for lesion-symptom mapping. In addition, probabilistic tract mapping and anatomical connectivity mapping will be conducted on the diffusion data to examine white matter tissue integrity. Both the lesion and white matter integrity measures will be related to performance using voxel based correlational methodology. The resting-state	—

Measure

Time frame

The primary outcome measure will be interpreted in the context of participants' global and individual performance on cognitive screening using the Addenbroke’s Cognitive Examination (ACE-R), the Picture Naming Task (IPNP), the National Adult Reading Test (IPNP) and Pyramids and Palm Trees (PPT) Test at baseline. Also correlational and regression analyses will be used to explore if other factors such as, time of diagnosis or number of relapses collected by reviewing the participant’s medical records contribute to anomia. The nature of anomia will be interpreted through in-depth neuropsychological assessment, along with the knowledge of the areas of the brain that have been affected by MS. A one-time MRI scan of each participant 3 months after the cognitive screening and an in-depth neuropsychological assessment including the Western Aphasia Battery (WAB), the Boston Naming Test (BNT), the Wisconsin Card Sort Test (WST), Test of Everyday Attention (TEA) and the Symbol Digits Modality Test (SDMT) within a week of the scan will be used. A probabilistic tract mapping and anatomical connectivity mapping will be conducted on the diffusion data to examine white matter tissue integrity. Both the lesion and white matter integrity measures will be related to performance using voxel based correlational methodology. The resting-state functional connectivity data will be processed via DPARSF (http://rfmri.org/DPARSF), and the resulting functional networks will be identified and examined in relation to both the behavioural and structural connectivity data. MS lesions will be identified manually from the T1 and T2 scans for lesion-symptom mapping. In addition, probabilistic tract mapping and anatomical connectivity mapping will be conducted on the diffusion data to examine white matter tissue integrity. Both the lesion and white matter integrity measures will be related to performance using voxel based correlational methodology. The resting-state

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026